文献速递银屑病与炎症性皮肤病

Izokibep治疗中重度斑块状银屑病的II期剂量探索研究

Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment.
PubMed 文献 · Br J Dermatol · 2023-01-01

AFFIRM-35是一项II期随机双盲安慰剂对照剂量探索研究,纳入109例中重度斑块状银屑病患者,随机接受安慰剂或izokibep 2、20、80、160 mg每2周一次治疗12周。第12周PASI 90应答率在安慰剂组为0%、80 mg组为71%、160 mg组为59%,药物总体耐受良好,高剂量组疗效维持至3年。

要点

  • 第12周PASI 90应答率:安慰剂组0%、izokibep 80 mg组71%、160 mg组59%。
  • Izokibep组不良事件与安慰剂相似,除轻度注射部位反应外。
  • 高剂量组疗效维持至3年,未发现新的安全性信号。

核心结论

  • Izokibep在中重度斑块状银屑病患者中耐受良好且有效,高剂量组疗效可维持至3年。

研究设计与样本

  • II期随机、双盲、安慰剂对照、剂量探索、多中心研究(AFFIRM-35),纳入109例对两种及以上标准治疗应答不足的中重度斑块状银屑病成人患者。
  • 患者按1:1:1:1:1随机接受安慰剂或izokibep 2、20、80、160 mg每2周一次治疗12周,随后52周核心研究期内安慰剂组转为izokibep 80 mg,并根据PASI评分调整给药间隔。
  • 核心研究后有两个可选的一年延长期,总疗程3年。

主要发现

  • 第12周PASI 90应答率:安慰剂组0%、izokibep 2 mg组5%、20 mg组19%、80 mg组71%、160 mg组59%。
  • 其他疗效指标也观察到快速且剂量依赖的改善。
  • 安慰剂对照期间,izokibep组不良事件与安慰剂相似,除轻度注射部位反应外;不良事件多为轻至中度。
  • 高剂量组疗效维持至3年,未发现新的安全性信号。

关键数值与推荐

  • 主要终点为第12周PASI 90应答率。
  • 安全性集108例(1例因不符合入选标准被排除),全分析集106例。

临床怎么用

  • 研究提示izokibep在中重度斑块状银屑病中耐受良好且有效,高剂量组PASI 90应答率较高。
  • 原文结论指出可探索更高剂量或更频繁给药以进一步提高应答率。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Monoclonal antibodies to interleukin (IL)-17 have shown strong efficacy in patients with psoriasis. Izokibep is a unique IL-17A inhibitor with a small molecular size and favourable distribution to sites of inflammation. OBJECTIVES: To evaluate the dose response, efficacy and safety of izokibep in patients with plaque psoriasis. METHODS: In this double-blind, randomized, phase II dose-finding study (AFFIRM-35) in adults with moderate-to-severe plaque psoriasis and inadequate response to two or more standard therapies, patients were randomized (1:1:1:1:1) to placebo or izokibep 2, 20, 80 or 160 mg every 2 weeks for 12 weeks. During the remainder of the 52-week core study, patients given placebo were switched to izokibep 80 mg, and dosing intervals were adapted based on Psoriasis Area and Severity Index (PASI) scores for all patients. The core study was followed by two optional consecutive 1-year extension periods for a total duration of 3 years. The primary endpoint was a 90% reduction in PASI score (PASI 90) at week 12. Additional efficacy outcomes and adverse event (AE) rates were evaluated. RESULTS: In total, 109 patients were randomized [safety set, n = 108 (one exclusion criteria failure); full analysis set, n = 106]. At week 12, PASI 90 response rates were 0%, 5%, 19%, 71% and 59% for the placebo, 2-, 20-, 80- and 160-mg izokibep groups, respectively. Rapid dose-dependent improvements were also observed across other efficacy outcomes. During the placebo-controlled period, AEs in the izokibep groups were similar to placebo except for mild injection site reactions. AEs were generally mild to moderate and the drug was well tolerated. Izokibep maintained efficacy at the higher dosage groups for up to 3 years, with no new safety signals. CONCLUSIONS: Data from this phase II study indicate that izokibep is well tolerated and efficacious in the treatment of plaque psoriasis. Higher doses or more frequent dosing could be explored to further enhance response rates.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Gerdes S, Staubach P, Dirschka T, et al. Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment. Br J Dermatol. 2023. PMID: 37697683. doi:10.1093/bjd/ljad186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。